reports
Southern California Bancorp and California Bancorp Announce Receipt of...
Southern California Bancorp and California Bancorp Announce Receipt of Regulatory Approval for Merger of Equals SAN DIEGO and OAKLAND, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Southern California Bancorp (Nasdaq: BCAL) and California BanCorp (Nasdaq: CALB) announce they have received required regulatory approvals from the Office of the Comptroller of the Currency and the Federal Reserve Bank of San Francisco necessary to complete their previously announced merger of equals between the two bank holding companies and their respective subsidiaries, Bank of Southern California, N.A., and Cal...
Landmark Bancorp Inc: 1 director
A director at Landmark Bancorp Inc bought 1,050 shares at 18.961USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conf...
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Life Sciences Conference, taking place in New York City on May 13 and 14. On Tuesday, May 14, at 1:00 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat. A live webcast of the fireside chat can be accessed and on t...
CrossAmerica Partners LP Reports First Quarter 2024 Results
CrossAmerica Partners LP Reports First Quarter 2024 Results Allentown, PA, May 08, 2024 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Reports First Quarter 2024 Results Reported First Quarter 2024 Net Loss of $17.5 million that includes a $15.9 million loss on lease terminations with Applegreen, Adjusted EBITDA of $23.6 million and Distributable Cash Flow of $11.7 million compared to a Net Loss of $1.0 million, Adjusted EBITDA of $31.7 million and Distributable Cash Flow of $19.1 million for the First Quarter 2023Reported First Quarter 2024 Gross Profit for the Wholesale Segment of $27....
Prelude Therapeutics Reports First Quarter 2024 Financial Results and ...
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at AACR 2024 included first characterization of PRT7732, a highly-selective, orally bioavailable SMARCA2 degrader Operational leadership capabilities further strengthened by recent hires Chief Business Officer Sean Brusky and Senior Vice President, Investor Relations Robert Doody Current cash runway ...
Landmark Bancorp, Inc. Announces First Quarter Earnings Per Share of $...
Landmark Bancorp, Inc. Announces First Quarter Earnings Per Share of $0.51. Declares Cash Dividend of $0.21 per Share Manhattan, KS, May 01, 2024 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (“Landmark”; Nasdaq: LARK) reported diluted earnings per share of $0.51 for the three months ended March 31, 2024, compared to $0.48 per share in the fourth quarter of 2023 and $0.61 per share in the same quarter last year. Net earnings for the first quarter of 2024 amounted to $2.8 million, compared to $2.6 million in the prior quarter and $3.4 million for the first quarter of 2023. For the three month...
California BanCorp Reports Financial Results for the First Quarter End...
California BanCorp Reports Financial Results for the First Quarter Ended March 31, 2024 OAKLAND, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- California BanCorp (NASDAQ: CALB) (the “Company”), whose subsidiary is California Bank of Commerce, announced today its financial results for the first quarter ended March 31, 2024. The Company reported net income of $3.8 million for the first quarter of 2024, representing a decrease of $1.5 million, or 29%, compared to $5.3 million for the fourth quarter of 2023 and a decrease of $1.6 million, or 30%, compared to $5.4 million in the first quarter of...
Landmark Bancorp, Inc. Announces Conference Call to Discuss First Quar...
Landmark Bancorp, Inc. Announces Conference Call to Discuss First Quarter 2024 Earnings Manhattan, KS, April 25, 2024 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (Nasdaq: LARK) announced that it will release earnings for the first quarter of 2024 after the market closes on Wednesday, May 1, 2024. The Company will host a conference call to discuss these results on Thursday, May 2, 2024 at 10:00 am (CT). Investors may listen to the Company’s earnings call via telephone by dialing (833) 470-1428 and using access code 688391. Investors are encouraged to call the dial-in number at least 5 minut...
West Bancorporation, Inc. Announces First Quarter 2024 Financial Resul...
West Bancorporation, Inc. Announces First Quarter 2024 Financial Results and Declares Quarterly Dividend WEST DES MOINES, Iowa, April 25, 2024 (GLOBE NEWSWIRE) -- West Bancorporation, Inc. (Nasdaq: WTBA; the “Company”), parent company of West Bank, today reported first quarter 2024 net income of $5.8 million, or $0.35 per diluted common share, compared to fourth quarter 2023 net income of $4.5 million, or $0.27 per diluted common share, and first quarter 2023 net income of $7.8 million, or $0.47 per diluted common share. On April 24, 2024, the Company’s Board of Directors declared a regul...
CrossAmerica Partners LP Maintains Quarterly Distribution
CrossAmerica Partners LP Maintains Quarterly Distribution Allentown, PA, April 22, 2024 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Maintains Quarterly Distribution Quarterly distribution of $0.5250 per unit attributable to the first quarter of 2024 ALLENTOWN, PA (April 22, 2024) – CrossAmerica Partners LP (NYSE: CAPL) announced today that the Board of Directors of its general partner has approved a quarterly distribution of $0.5250 per unit attributable to the first quarter of 2024 (annualized $2.10 per unit). The distribution attributable to the first quarter is payable on May 10, ...
CrossAmerica Partners to Announce First Quarter 2024 Earnings Results ...
CrossAmerica Partners to Announce First Quarter 2024 Earnings Results on May 8 Allentown, PA, April 17, 2024 (GLOBE NEWSWIRE) -- CrossAmerica Partners to Announce First Quarter 2024 Earnings Results on May 8 ALLENTOWN, PA, April 17, 2024 – CrossAmerica Partners LP (NYSE: CAPL) today announced that it will release its first quarter 2024 results after the market closes on Wednesday, May 8, 2024. In conjunction with the news release, management will host a conference call on Thursday, May 9 at 9:00 a.m. Eastern Time. The conference call numbers are 800-717-1738 or 646-307-1865 and the pa...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
VIRC VIRCO MANUFACTURING CORP.
MDWD MEDIWOUND
NEM NEMETSCHEK SE
ARO ARCANDOR AG
CSTE CAESARSTONE LTD.
AGX ARGAN INC.
AMRK AMARK PRECIOUS METALS
EVER EVERQUOTE
RPAY REPAY HOLDINGS (A)
IGMS IGM BIOSCIENCES
PRLD PRELUDE THERAPEUTICS
DFH DREAM FINDERS HOMES
GATO GATOS SILVER
CPNG COUPANG
TPL TEXAS PACIFIC LAND CORPORATION
RANI RANI THERAPEUTICS HLDGS INC
JANX JANUX THERAPEUTICS INC
ALVO OAKTREE ACQUISITION CORP II
IE IVANHOE ELECTRIC INC
ACRV ACRIVON THERAPEUTICS INC
IZM ICZOOM GROUP INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
PRAX PRAXIS PRECISION MEDICINES INC
EGIO EDGIO INC.
FIP FIAT INDUSTRIAL SPA
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR...
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematological models as monotherapy and provides improved depth and duration of response in combination with BTK/BCL2 inhibition Next Generation CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted thera...
West Bancorporation, Inc. to Announce Quarterly Results, Hold Conferen...
West Bancorporation, Inc. to Announce Quarterly Results, Hold Conference Call WEST DES MOINES, Iowa, March 22, 2024 (GLOBE NEWSWIRE) -- West Bancorporation, Inc. (Nasdaq: WTBA) (the “Company”), parent company of West Bank, will report its results for the first quarter of 2024 on Thursday, April 25, 2024 before the markets open. The Company will discuss its results in a conference call scheduled for 2:00 p.m. Central Time on Thursday, April 25, 2024. The telephone number for the conference call is 800-715-9871. The conference ID for the conference call is 8178676. A recording of the call ...
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the ...
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been accepted for presentation at the ...
Prelude Therapeutics to Participate in Barclays Global Healthcare Conf...
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024. On Wednesday, March 13, at 3:05 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat, hosted by Barclays. A live webcast of the fireside chat can be accessed and...
CrossAmerica Partners Files 2023 Annual Report on Form 10-K
CrossAmerica Partners Files 2023 Annual Report on Form 10-K Allentown, PA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- CrossAmerica Partners Files 2023 Annual Report on Form 10-K ALLENTOWN, PA, February 28, 2024 – CrossAmerica Partners LP (NYSE: CAPL) on February 27, 2024 has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (SEC). The filing can be viewed through a link on the Partnership's website at or on the SEC's website at . The Partnership's unitholders may request a printed copy of the report, which contains ...
CrossAmerica Partners LP Reports Fourth Quarter and Full Year 2023 Res...
CrossAmerica Partners LP Reports Fourth Quarter and Full Year 2023 Results Allentown, PA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Reports Fourth Quarter and Full Year 2023 Results Reported Fourth Quarter 2023 Net Income of $16.7 million, Adjusted EBITDA of $47.6 million and Distributable Cash Flow of $35.8 million compared to Fourth Quarter 2022 Net Income of $17.1 million, Adjusted EBITDA of $44.3 million and Distributable Cash Flow of $33.3 millionGenerated Full Year 2023 Net Income of $42.6 million, Adjusted EBITDA of $165.8 million and Distributable Cash Flow of ...
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outl...
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024 First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in first half and enter Phase 1 clinical trial in second half of 2024 Recently established partnership with AbCellera to jointly discover, develop, and commercialize a portfolio of next generation precision ADCs Current cash runway into 2026 with $232.9 million in cash, cash equiva...
Landmark Bancorp, Inc. Announces Fourth Quarter Earnings Per Share of ...
Landmark Bancorp, Inc. Announces Fourth Quarter Earnings Per Share of $0.48 Declares Cash Dividend of $0.21 per Share Manhattan, KS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (“Landmark”; Nasdaq: LARK) reported diluted earnings per share of $0.48 for the three months ended December 31, 2023, compared to $0.53 per share in the third quarter of 2023 and $0.22 per share in the same quarter last year. Net earnings for the fourth quarter of 2023 amounted to $2.6 million, compared to $2.9 million in the prior quarter and $1.2 million for the fourth quarter of 2022. For the three...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.